Close mobile menu×
Close mobile menu

Denise E. Chou, MD

Board Certifications: 
Neurology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-6876

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Neurology

Clinical Expertise

  • Headache
  • Facial Pain

Specialties

Education & Training

  • Weill Cornell Medical College
  • Internship: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  • Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
  • Fellowship: University of California San Francisco Medical Center

About Denise Chou

Denise Chou, M.D., obtained her undergraduate degree from Harvard College and her medical degree from Cornell University. She subsequently completed her internship in internal medicine and neurology residency at New York-Presbyterian Hospital/Weill-Cornell campus, followed by a fellowship in headache medicine at the University of California at San Francisco. In addition to outpatient management of headache, she has expertise in procedural therapies, including occipital nerve blocks and Botox injections for chronic headache. She will also be developing an inpatient headache program for refractory headaches using intravenous medication protocols, including an effective detoxification protocol for medication overuse headache. Dr. Chou is committed to delivering the highest level of specialized care to her patients by promoting patient education and creating a tiered headache treatment plan that targets abortive, preventive, and rescue strategies for each individual.

Academic Titles

  • Assistant Professor of Neurology

Administrative Positions

  • Director, Columbia University Headache Center

Committee/Societies/Council Memberships

  • American Academy of Neurology
  • American Headache Society
  • International Headache Society

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

AARP

  • Medicare Managed Care

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Blue Shield

  • New Jersey

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Indemnity
  • Medicare (Mediblue)
  • Medicare Managed Care
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
51 West 51st Street
Suite 380
New York, New York 10019
Phone: (212) 305-6876
Fax:
(212) 326-8530
Primary

Research

Grants

A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ALD403 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH CHRONIC MIGRAINE (P&S Industry Clinical Trial)

Apr 19 2017 - Apr 19 2022

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS (INTRAVENOUS/SUBCUTANEOUS AND SUBCUTANEOUS) OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTION OF EPISODIC (P&S Industry Clinical Trial)

Apr 6 2017 - Apr 6 2022

OPEN-TRIAL ON THE ACUTE TREATMENT OF MIGRAINE USING THE CEFALY DEVICE (P&S Industry Clinical Trial)

Apr 2 2015 - Apr 2 2020